The first clinical trial focused on the use of Olaparib, and included patients with positive pathogenic BRCA1/2 mutations, Her2 negative, locally advanced, or metastatic cancer that have been previously treated by chemotherapy (OlympiAD) [42]. The gene discussed is BRCA1; the disease is metastatic malignant neoplasm.